| Literature DB >> 36110903 |
Nicolas S Bodmer1,2, Carla Wirth1,2, Veronika Birkhäuser1, Andrea M Sartori1,3, Lorenz Leitner1, Marcio A Averbeck4, Stefan de Wachter5, Enrico Finazzi Agro6,7, Andrew Gammie8, Howard B Goldman9, Ruth Kirschner-Hermanns10,11, Peter F W M Rosier12, Maurizio Serati13, Eskinder Solomon14, Gommert van Koeveringe15, Lucas M Bachmann2, Thomas M Kessler1.
Abstract
Context: The role of urodynamic studies (UDSs) in the diagnosis of lower urinary tract symptoms (LUTS) is crucial. Although expert statements and guidelines underline their value for clinical decision-making in various clinical settings, the academic debate as to their impact on patient outcomes continues. Objective: To summarise the evidence from all randomised controlled trials assessing the clinical usefulness of UDS in the management of LUTS. Evidence acquisition: For this systematic review, searches were performed without language restrictions in three electronic databases until November 18, 2020. The inclusion criteria were randomised controlled study design and allocation to receive UDS or not prior to any clinical management. Quality assessment was performed by two reviewers independently, using the Cochrane Collaboration's tool for assessing the risk of bias. A random-effect meta-analysis was performed on the uniformly reported outcome parameters. Evidence synthesis: Eight trials were included, and all but two focused on women with pure or predominant stress urinary incontinence (SUI). A meta-analysis of six studies including 942 female patients was possible for treatment success, as defined by the authors (relative risk 1.00, 95% confidence interval: 0.93-1.07), indicating no difference in efficacy when managing women with UDS. Conclusions: Although UDSs are not replaceable in diagnostics, since there is no other equivalent method to find out exactly what the lower urinary tract problem is, there are little data supporting its impact on outcomes. Randomised controlled trials have focussed on a small group of women with uncomplicated SUI and showed no added value, but these findings cannot be extrapolated to the overall patient population with LUTS, warranting further well-designed trials. Patient summary: Despite urodynamics being the gold standard to assess lower urinary tract symptoms (LUTS), as it is the only method that can specify lower urinary tract dysfunction, more studies assessing the clinical usefulness of urodynamic studies (UDSs) in the management of LUTS are needed. UDS investigation is not increasing the probability of success in the treatment of stress urinary incontinence.Entities:
Keywords: Lower urinary tract symptoms; Prostatic hyperplasia; Stress; Urinary incontinence; Urodynamics
Year: 2022 PMID: 36110903 PMCID: PMC9469658 DOI: 10.1016/j.euros.2022.08.013
Source DB: PubMed Journal: Eur Urol Open Sci ISSN: 2666-1683
Fig. 1Preferred Reporting Items for Systematic Reviews and Meta-analyses flow diagram.
Population, baseline characteristics
| Author (year) | Recruitment start | Follow-up/duration (mo) | Number of centres | Noninferiority trial (Y/N) | Number of patients | Mean age (SD) | Mean BMI | Mean duration of symptoms (mo) | Previous surgery (eg, hysterectomy) | Postmenopausal |
|---|---|---|---|---|---|---|---|---|---|---|
| Agarwal (2014) | Sept 2011 | 12 | NR | N | Arm 1: 30 | Arm 1: 49.9 (11.4) | Arm 1: 26.4 | NR | Arm 1: 70.0% | Arm 1: 43.3% |
| de Lima (2003) | Mar 1993 | 6 | NR | N | Arm 1: 164 | Arm 1: 61 | NR | NR | NR | NA |
| Drake (2020) | Oct 2014 | 18 | 26 | Y | Arm 1: 427 | Arm 1: 67.5 (9.6) | NR | NR | NR | NA |
| Holtedahl (2000) | 1994 | 12 | NR | N | Arm 1: 45 | Arm 1: 60.0 (6.3) | Arm 1: 26.8 | NR | NR | NR |
| Nager (2012) | Nov 2008 | 12 | 11 | Y | Arm 1: 264 | Arm 1: 51.9 (10.4) | Arm 1: 29.1 | Arm 1: 107.4 | Arm 1: 67.8% | Arm 1: 45.1% |
| Maroto (2010) | Sept 2004 | Arm 1: 46 | NR | N | Arm 1: 42 | NR | NR | NR | NR | NR |
| van Leijsen (2012) | Aug 2007 | 24 | 10 | Y | Arm 1: 31 | Arm 1: 44 | Arm 1: 26 | NR | Arm 1: 20% | Arm 1: 33% |
| van Leijsen (2013) | 2009 | 24 | 30 | Y | Arm 1: 62 | Arm 1: 54 (14) | Arm 1: 27 | NR | Arm 1: 27% | NR |
Arm 1 = urodynamic evaluation; Arm 2 = without urodynamic evaluation; Aug = August; BMI = body mass index; N = no; Mar = March; NA = not applicable; Nov = November; NR = not reported; SD = standard deviation; Sept = September; Oct = October; Y = yes.
Age, BMI, parity, menopause, and number of pads were similar in both groups.
Inclusion/exclusion criteria and type of urodynamic studies
| Author | Year | Inclusion criteria | Exclusion criteria | Type of urodynamics |
|---|---|---|---|---|
| Agarwal | 2014 | Women presenting with predominant SUI (defined as involuntary leakage during physical activity, coughing, or sneezing) underwent a standardised basic office evaluation and were eligible for the study if they had a history of symptoms of uncomplicated SUI for at least 3 mo and failure to respond to standard medical treatment and pelvic floor exercises, postvoid residual of <150 ml, negative urine culture to exclude urinary tract infection, desire for surgery for SUI, and positive provocative stress test (defined as an observed transurethral loss of urine that was simultaneous with a cough or Valsalva manoeuvre). The provocative stress test, which had to be positive for inclusion in the study, was performed at the time of cystoscopic confirmation for SUI at a volume of approximately 300 ml along with a Bonney test. A clinical assessment of urethral mobility (defined as a straining angle of ≥30° relative to the horizontal on the Q-tip test) was also conducted at the same time. | Exclusion criteria were previous surgery for incontinence, history of pelvic irradiation, pelvic surgery within the previous 3 mo, and anterior or apical pelvic organ prolapse beyond 1 cm proximal to the hymen (stage II and higher of the pelvic organ prolapse quantification system). A random 150 ml cut-off for postvoid residual was chosen to exclude most patients with voiding dysfunction or neurogenic lower urinary tract dysfunction. | Standardised urodynamic testing included noninvasive uroflowmetry, filling cystometry with VLPP, urodynamic stress test, pressure flow studies, and urethral pressure profilometry. These were performed on the urodynamic group prior to surgery by the use of a multichannel urodynamics system (Dorado KT; Laborie, Toronto, ON, Canada). The International Continence Society–recommended Good Urodynamic Practice Guidelines were adhered to in the research. Conventional filling cystometry was performed with the patients in the supine position by using a 6 French double lumen catheter. The bladder was filled at a constant rate of 20 m/min by using normal saline solution at room temperature for standard urodynamic study. Simultaneous abdominal pressure monitoring was obtained through a fluid-filled rectal balloon catheter. Pressures were measured by using external pressure transducers that were zeroed to atmospheric pressure by using the level of the symphysis pubis as the reference height. The presence of involuntary detrusor contractions with or without incontinence was documented, and VLPP was obtained at a bladder volume of 200 ml. With the patient having a full bladder, the resting urethral pressure profile was obtained by using a 6 French catheter, catheter withdrawal, and water perfusion. The mean maximum urethral closure pressure of three successive withdrawals was used for a statistical analysis. Pressure flow study was subsequently performed with maximum cystometric capacity. |
| De Lima | 2003 | Male patients with LUTS submitted to transurethral resection of the prostate were included. | Patients were excluded from the study if they had been exposed to drugs, such as alpha-agonists, anticholinergics, cholinergics, diuretic agents, oestrogens, androgens, antihypertensive medications, or other agents within the previous 2 wk. Other exclusion criteria consisted of a history or evidence of prostate cancer, pelvic irradiation, urethral stricture, or surgery for benign prostatic hyperplasia, or evidence of active urinary tract stone disease, neurogenic lower urinary tract dysfunction, hydronephrosis, or urinary tract infection within the 3 mo before the study. | Urodynamic evaluation was performed using the Urosystem/DS-5600 apparatus, connected to a 6 French rectal catheter for recording the abdominal pressure and a 6 French urethral catheter for recording the vesical pressure, with the patient standing. The catheters were connected to pressure transducers located at the level of the patient’s pubic symphysis. For the filling of the bladder, 0.9% saline infusion was introduced via an 8 French urethral catheter at an infusion rate of 50 ml/min. The vesical and abdominal pressures were recorded, as well as the detrusor pressure (defined as the vesical pressure minus the abdominal pressure) and uroflow rate. This examination included cystometry and pressure flow study, and in all patients, the measures were obtained in duplicate. The bladder outlet obstruction factor was defined in accordance with the criteria established by the International Continence Society. Utilising the Qmax and the PdetQmax, it was seen that: (1) when PdetQmax – 2 Qmax is >40, the pressure flow study indicates obstruction; (2) when PdetQmax – 2 Qmax is <20, the pressure flow study indicates absence of obstruction; and (3) in intermediate situations, the test result is equivocal obstruction. |
| Drake | 2020 | Men (>18 yr old) with bothersome LUTS, in whom surgery was potentially being considered, were included. | The exclusion criteria were catheter use for bladder emptying, relevant neurological disease, current treatment for prostate or bladder cancer, previous prostate surgery, unfit for surgery, and/or unwillingness to comply with trial requirements. | Quality of urodynamic testing was according to the International Continence Society Good Urodynamic Practice requirements. It included the following: filling cystometry (detrusor overactivity and maximum cystometric capacity [ml]), pressure flow study (voided volume [ml], Qmax [ml/s], and postvoid residual [ml]), Bladder Contractility Index, and Bladder Outlet Obstruction Index. All 26 participating centres were checked for compliance with the international requirements beforehand. |
| Holtedahl | 2000 | Inclusion criteria included fulfilling the International Continence Society criteria for urinary incontinence. Leakage was objectively demonstrated in at least one of three ways: visible leakage on coughing during the gynaecological examination, a positive 48 h pad test, or a recording of “wet” on a 48 h frequency-volume chart. The woman’s informed consent to participate in the treatment study was accepted as a confirmation that the patient experienced a social or hygienic problem, and only women reporting two or more leakage episodes per month were invited to join the study. | Urodynamic examination was performed by the two gynaecologist authors, one at Tromsø University Hospital and the other at Nordland Central Hospital in Bodø. The examination consisted of measurement of postvoid residual, filling of the bladder with 300 ml water at 37°C, urethral pressure profile, stress test by coughing, and subsequently 20 split jumps with pad weighing before and after, followed by cystometry, cystoflowmetry, cystoscopy (omitted on repeat examination), and gynaecological examination. | |
| Nager | 2012 | Women presenting with urinary incontinence underwent a standardised basic office evaluation and were eligible for the study if they were 21 yr of age or older, had a history of symptoms of SUI for at least 3 mo, and had a score on the Medical, Epidemiological, and Social Aspects of Aging questionnaire for SUI that was greater than the score on this questionnaire or urgency incontinence, postvoid residual of <150 ml, negative urinalysis or urine culture, clinical assessment of urethral mobility, desire for surgery for SUI, and positive provocative stress test (defined as an observed transurethral loss of urine simultaneous with a cough or Valsalva manoeuvre at any bladder volume). | Exclusion criteria were previous surgery for incontinence, history of pelvic irradiation, pelvic surgery within the previous 3 mo, and anterior or apical pelvic-organ prolapse of ≥1 cm distal to the hymen. | Women in the urodynamic-testing group underwent noninstrumented uroflowmetry with a comfortably full bladder, filling cystometry with VLPP, and a pressure-flow study. Urethral pressure profilometry or urodynamic testing with the use of video was permitted if it was performed routinely as part of the preoperative investigation at the study site. Testing followed the Good Urodynamic Practice guidelines of the International Continence Society, and interpretation conformed to International Continence Society nomenclature. |
| Maroto | 2010 | Women with stress or mixed urinary incontinence were included | Patients younger than 18 yr of age and those who have had radiotherapy or any anti-incontinence procedure were excluded. | Urodynamics was used to determine maximum cystometric capacity (ml), detrusor pressure at Qmax (cmH2O), VLPP (cmH2O), and detrusor overactivity (%) |
| van Leijsen | 2012 | Women were eligible for the study when they had SUI or MUI with predominant symptoms of SUI. To be included, conservative therapy must have failed, and patients were opting or candidates for surgical treatment. Furthermore, incontinence suggestive for SUI must have been demonstrated on physical examination and/or bladder diary. | Patients with previous incontinence surgery, pelvic organ prolapse >1 cm beyond the level of the hymen (POP-Q stage 3 or more), and/or postvoid residual of >150 ml on ultrasound or catheterisation were excluded. | Urodynamics investigation was performed according to the International Continence Society standards, and consisted of free uroflowmetry and postvoid residual measurement, filling cystometry with abdominal leak point pressure measurement, and pressure flow study. Urethral pressure profilometry in rest and during stress was optional. Eight centres used urodynamic equipment of Medical Measurement Systems, one centre used Andromeda equipment, and the remaining centre used equipment of Medtronic. The catheters (in two centres air charged; in eight centres water filled) had a size of 7 French. Standard filling speed was 50 ml/min; filling and voiding cystometry were performed with the patient in sitting position. For every 100 ml, a cough test was performed. |
| van Leijsen | 2013 | Women with uncomplicated SUI considered as symptoms of pure SUI or MUI with predominant SUI symptoms, who had previously failed conservative therapy and were candidates for surgical therapy, were eligible for study inclusion. SUI was defined as self-reported complaints of involuntary loss of urine on effort, physical exertion, coughing, or sneezing. Women were considered to have predominant SUI in cases in which they reported the complaint of SUI and also involuntary loss of urine associated with urgency symptoms, and experienced the most bother of the stress component. SUI must have been demonstrated on physical examination or indicated on bladder diary, or both. A cough stress test was performed in the lithotonic position with a subjective full bladder. Postvoid residual was measured by catheterisation, ultrasonography, or bladder scan. | Patients were excluded if they had prior incontinence surgery or pelvic organ prolapse with the leading edge of prolapse at least 1 cm beyond the level of the hymen, or if a postvoid residual of ≥150 ml was present on ultrasonography or catheterisation. | All eligible women underwent urodynamics performed according to the International Continence Society standards. Free uroflowmetry was assessed using the Liverpool diagram. Measured parameters were Qmax (ml/s), postvoid residual (ml), maximum cystometric maximum (ml), and maximum urethral closure pressure (mmHg). |
LUTS = lower urinary tract symptoms; MUI = mixed urinary incontinence; PdetQmax = detrusor pressure at the maximum flow rate; Qmax = maximum flow rate; SUI = stress urinary incontinence; VLPP = Valsalva leak point pressure.
Results successful/unsuccessful treatment/classification
| Author (year) | Urodynamic group: improvement ( | Urodynamic group: no improvement ( | Nonurodynamic group: improvement ( | Nonurodynamic group: no improvement ( | Definition of improvement |
|---|---|---|---|---|---|
| Agarwal (2014) | 27 | 3 | 20 | 10 | Reduction in the Urogenital Distress Inventory (UDI-6) score of ≥70% at 12 mo after the onset of treatment |
| De Lima (2003) | 148 | 16 | 124 | 27 | No obstruction after TURP surgery based only on urodynamics (urodynamic criteria listed in |
| Drake (2020) | 255 | 153 | 246 | 138 | Improvement assessment = surgical rates within 18 mo of randomisation: |
| Holtedahl (2000) | 25 | 19 | 24 | 17 | Improvement = cured and improved |
| Nager (2012) | 210 | 62 | 210 | 56 | Reduction in the UDI-6 score of ≥70% |
| Maroto (2010) | 41 | 1 | 43 | 1 | Urinary incontinence grade cough test: improvement = dry + improved; no improvement = failure |
| van Leijsen (2012) | 17 | 14 | 20 | 8 | Total cure of SUI was defined as the combination of total subjective and total objective cure. (Subjective cure of SUI was defined as a no leakage reported during physical activity [UDI]. Objective cure of SUI was defined as a negative stress test by physical examination.) |
| van Leijsen (2013) | 42 | 14 | 43 | 15 | Absence of SUI after 1 yr (urodynamic = individually tailored treatment; nonurodynamic = surgery) |
SUI = stress urinary incontinence; TURP = transurethral resection of the prostate; UDI = urodynamic investigation.
No statistical significant difference regarding symptoms/uroflow.
Quality assessment items
| Author (year) | Random sequence generation | Stratified randomisation | Allocation concealment | Blinding of patients | Blinding of therapists | Blinding of outcome assessors | Incomplete outcome data | Selective reporting | Baseline similarity of the arms | Patient flowchart reported | Intention-to-treat-analysis | Per-protocol analysis | Missing data | Dropouts/withdrawals, |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agarwal (2014) | NR | NR | Unclear | Unclear | Yes | Unclear | Yes | No | Yes | Yes | Unclear | Unclear | Unclear | 12 (17) |
| De Lima (2003) | NR | NR | Unclear | Unclear | Unclear | Unclear | No | No | Unclear | Yes | Unclear | Unclear | Unclear | 0 (0) |
| Drake (2020) | Telephone/web-based system (computer-based randomisation) | No | Yes | No | No | No | No | No | Yes | Yes | Yes | Yes | No | 151 (18) |
| Holtedahl (2000) | Random number table | NR | Yes | No | No | Yes | Yes | Yes | Yes | No | Unclear | Unclear | Unclear | 3 (4) |
| Nager (2012) | Automated randomisation system | By surgeon | Yes | No | No | Yes | No | No | No | Yes | Yes | Yes | Unclear | 107 (17) |
| Maroto (2010) | NR | NR | Unclear | Unclear | Unclear | Unclear | No | No | Yes | Unclear | Unclear | Unclear | Unclear | 0 (0) |
| van Leijsen (2012) | Computer-generated with remote computer access, blinded block sizes | By centre with a 1:1 allocation | Yes | No | No | No | No | No | Yes | Yes | Yes | No | LOCF | 0 (0) |
| van Leijsen (2013) | Web-based application, block randomisation, variable block size (2–8) | By centre with a 1:1 allocation | Yes | No | No | Yes | No | No | Yes | No | Yes | Yes | Unclear | 11 (9) |
LOCF = last observation carried forward; NR = not reported.
Post hoc analysis with adjustment for baseline differences did not alter the findings.
Fig. 2Meta-analysis (random-effect model) summarising the efficacy of urodynamic studies for treatment success. Treatment success is defined as symptom improvement as defined individually in the different studies. CI = confidence interval; RR = relative risk.